Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382870 | 0.99 | JAK2 (0.36) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10285219 | 0.88 | JAK2 (0.35) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605212 | 0.84 | JAK2 (0.36) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605209 | 0.84 | JAK2 (0.36) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605427 | 0.83 | JAK2 (0.35) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605303 | 0.83 | JAK2 (0.35) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605306 | 0.83 | JAK2 (0.35) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1604882 | 0.82 | EPHX2 (0.36) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL10284770 | 0.81 | EPHX2 (0.35) | JAK2JAK1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1605816 | 0.81 | EPHX1 (0.40) | JAK2JAK1P2RX7GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | JAK2 4247/4885JAK1 3780/4885TAS1R3 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.